KalVista Pharmaceuticals Inc (KALV)
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
📈 **POSITIVE** • High confidence analysis (81%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business